| Term 
 | Definition 
 
        | nitrogen mustards, platinum analogs; MOA: cross linking DNA or base pairs, cell cycle non-spec. |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | cyclophosphamides, ifosfamide, melphalan, bendamustine, chlorambucil |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | cisplatin (platinol), carboplatin (paraplatin), oxaliplatin (eloxatin) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | neuropathy; cold sensitivity, pharyngo-laryngeal dysthesia |  | 
        |  | 
        
        | Term 
 
        | myelosupression of platinums |  | Definition 
 
        | carboplatin= thrombocytopenia, cisplatin= anemia |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | nitrosureas, ethylenines, alkyl sulfonates, triazenes |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | type I and II toperisomerase inhibitors, |  | 
        |  | 
        
        | Term 
 
        | topoisomerase II inhibitors (cell cycle non-specific) |  | Definition 
 
        | anthracyclines; daunorubacin, doxorubaci, epirubacin, valrubicin |  | 
        |  | 
        
        | Term 
 
        | topoisomerase II inhibitors (G-phase specific) |  | Definition 
 
        | epidophyllotoxins; etoposide, teniposide |  | 
        |  | 
        
        | Term 
 
        | myelosuppression-pancytopenia |  | Definition 
 
        | topo I (irinotecan, topotecan) topo II (rubacins, etoposide and teniposide), folate antagonists, |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | drug to protect against cardiotoxicity  and vesicant effects seen in rubacin administration; iron chelator that binds free radicals |  | 
        |  | 
        
        | Term 
 
        | non-specific cell cycle inhibitors |  | Definition 
 
        | nitrogen mustards, platinum agents, anthracyclines (rubacin/topo II inhib) |  | 
        |  | 
        
        | Term 
 
        | S phase specific cell cycle inhibitors |  | Definition 
 
        | topo I inhibitors (irinotecan, topotecan), purine analogues, pyrimidine analogs, folate analogues |  | 
        |  | 
        
        | Term 
 
        | m phase specific cell cycle inhibitors |  | Definition 
 
        | vinka alkaloids, taxanse, eribulin, exabepilone |  | 
        |  | 
        
        | Term 
 
        | G phase specific cell cycle inhibitors |  | Definition 
 
        | topo II ihibitors (etoposide, teniposide) and bleomycin |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | diarrhea, acute; use atropine, delayed; use loperamide |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | cladribine, clofarabine, fludabarine, pentostain, thoguanine, mercaptopurine (6-MP) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | capecitabine, cytarbine, gencetabin, fluoruracil (5-FU) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | methotrexate, pralatrexate, premetrexed |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | mucosal damage, nephrotoxicity, pancytopenia, |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | drug to decrease or prevent methotrexate toxicity |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | vincristine,vindesine, vinblastine, vinorelbine |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | mylosuppression (vinorelbine, vinblastine), vesicant, fatal if intrathecal admin, neurotoxicity, dose adjust for hepatic |  | 
        |  | 
        
        | Term 
 
        | topoisomerase I inhibitors |  | Definition 
 
        | canptotheicins; irinotecan, topotecan |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | paclitaxel, docetaxel, cabazitaxel |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | infusion HS caused by crephor; premedicate with H2, H1, steroid |  | 
        |  |